RVMD Stock Surges To All-Time Highs After 36% Jump – What’s Driving This Super Rally?

• Daraxonrasib significantly improved both progression-free and overall survival compared to standard chemotherapy.
• Patients treated with the drug lived a median of 13.2 months, compared with 6.7 months for those on chemotherapy.
• The firm stated that the study met all key endpoints.

Revolution Medicines (RVMD) drew the spotlight after its shares surged 36% on Monday morning, driven by strong Phase 3 results for its experimental drug Daraxonrasib to treat metastatic pancreatic cancer.

Trial Shows Better Results Than Standard Chemotherapy

In the RASolute 302 trial, Daraxonrasib significantly improved both progression-free and overall survival compared to standard chemotherapy. Patients treated with the drug lived a median of 13.2 months, compared with 6.7 months for those on chemotherapy, highlighting a meaningful benefit. The treatment was also generally well tolerated, with no new safety concerns reported.

The study met all key endpoints, and the company plans to submit the data to the U.S. Food and Drug Administration (FDA) and present it at the American Society of Clinical Oncology Annual Meeting in May.

“These results represent a potentially transformative advance for patients and underscore daraxonrasib’s potential to redefine the treatment landscape,” said Mark A. Goldsmith, CEO and chairman of Revolution Medicines.

Daraxonrasib Targets RAS-Driven Tumors

Pancreatic cancer is heavily driven by RAS gene mutations, with over 90% of patients affected by these aggressive genetic changes. Daraxonrasib is a new drug designed to target a broad range of RAS-driven tumors.

In the trial, patients received either a daily oral dose of Daraxonrasib or standard chemotherapy chosen by doctors. The study mainly measured progression-free and overall survival in patients with specific RAS mutations, while also tracking results across all participants. It also evaluated response rates, duration of benefit, and quality of life.

While Daraxonrasib has not yet been approved in the U.S. or Europe, it has received special designations from the FDA to expedite its development for pancreatic cancer.

How Did Retail Traders React?

Retail sentiment for RVMD on Stocktwits turned ‘extremely bullish’ from ‘bullish’ amid ‘extremely high’ message volumes.

Users spoke about a potential buyout following the results.

RVMD shares have gained more than 220% so far this year.

For updates and corrections, email newsroom[at]stocktwits[dot]com.